JP2025507915A - ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用 - Google Patents
ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用 Download PDFInfo
- Publication number
- JP2025507915A JP2025507915A JP2024552219A JP2024552219A JP2025507915A JP 2025507915 A JP2025507915 A JP 2025507915A JP 2024552219 A JP2024552219 A JP 2024552219A JP 2024552219 A JP2024552219 A JP 2024552219A JP 2025507915 A JP2025507915 A JP 2025507915A
- Authority
- JP
- Japan
- Prior art keywords
- heterocycloalkyl
- cycloalkyl
- alkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022078655 | 2022-03-01 | ||
| CNPCT/CN2022/078655 | 2022-03-01 | ||
| CNPCT/CN2022/091215 | 2022-05-06 | ||
| CN2022091215 | 2022-05-06 | ||
| CNPCT/CN2022/128282 | 2022-10-28 | ||
| CN2022128282 | 2022-10-28 | ||
| CN2023071962 | 2023-01-12 | ||
| CNPCT/CN2023/071962 | 2023-01-12 | ||
| PCT/CN2023/078973 WO2023165509A1 (en) | 2022-03-01 | 2023-03-01 | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507915A true JP2025507915A (ja) | 2025-03-21 |
| JP2025507915A5 JP2025507915A5 (https=) | 2026-03-09 |
Family
ID=87883015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552219A Pending JP2025507915A (ja) | 2022-03-01 | 2023-03-01 | ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250214990A1 (https=) |
| EP (1) | EP4486745A4 (https=) |
| JP (1) | JP2025507915A (https=) |
| CN (1) | CN118829642A (https=) |
| AR (1) | AR128668A1 (https=) |
| TW (1) | TW202342478A (https=) |
| WO (1) | WO2023165509A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4486741A4 (en) | 2022-03-01 | 2026-04-08 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| WO2025051110A1 (en) * | 2023-09-04 | 2025-03-13 | Insilico Medicine Ip Limited | Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011075747A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Therapeutic compounds |
| KR102767739B1 (ko) * | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| US20230062100A1 (en) * | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| BR112022012179A2 (pt) * | 2019-12-23 | 2022-09-06 | Bristol Myers Squibb Co | Compostos de quinazolina substituída úteis como ativadores de célula t |
| IL294032A (en) * | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| MX2023014762A (es) * | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
-
2023
- 2023-03-01 JP JP2024552219A patent/JP2025507915A/ja active Pending
- 2023-03-01 EP EP23762907.6A patent/EP4486745A4/en active Pending
- 2023-03-01 CN CN202380024556.1A patent/CN118829642A/zh active Pending
- 2023-03-01 WO PCT/CN2023/078973 patent/WO2023165509A1/en not_active Ceased
- 2023-03-01 AR ARP230100508A patent/AR128668A1/es unknown
- 2023-03-01 US US18/841,639 patent/US20250214990A1/en active Pending
- 2023-03-01 TW TW112107273A patent/TW202342478A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118829642A (zh) | 2024-10-22 |
| EP4486745A1 (en) | 2025-01-08 |
| WO2023165509A1 (en) | 2023-09-07 |
| EP4486745A4 (en) | 2026-03-11 |
| TW202342478A (zh) | 2023-11-01 |
| AR128668A1 (es) | 2024-06-05 |
| US20250214990A1 (en) | 2025-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025507915A (ja) | ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用 | |
| JP7802106B2 (ja) | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 | |
| CA3069829A1 (en) | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor | |
| AU2014228574B2 (en) | SHIP1 modulators and methods related thereto | |
| CA3134261A1 (en) | 6-(isooxazolidin-2-yl)-n-phenylpyrimidin-4-amine derivatives as inhibitors of epidermal growth factor receptors | |
| JP2025508971A (ja) | ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用 | |
| WO2023066283A1 (en) | Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof | |
| JP2024541910A (ja) | プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤およびその使用方法 | |
| JP2026508072A (ja) | Ｋｉｆ１８ａの阻害薬およびその使用 | |
| TW202521544A (zh) | TNFα活性調節劑及其用途 | |
| EP4206197A1 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
| WO2023165525A1 (en) | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof | |
| TW202412760A (zh) | Cbl-b抑制劑及其使用方法 | |
| WO2024141015A1 (en) | Protein tyrosine phosphatase inhibitors and uses thereof | |
| EA052540B1 (ru) | Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения | |
| TW202440093A (zh) | Cdk8/19雙重抑制劑及其使用方法 | |
| WO2025261355A1 (en) | Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof | |
| WO2026024795A1 (en) | F-atp hydrolase inhibitors | |
| CN120712269A (zh) | Fgfr2和fgfr3的抑制剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260227 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260227 |